Kiora PharmaceuticalsNASDAQ: KPRX

Ken Gayron to Step Down as a Member of the Company's Board Encinitas, California--(Newsfile Corp. - July 1, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced that it has appointed Lisa Walters-Hoffert as an independent member to the Company's Board of Directors. Ms. Walters-Hoffert is a seasoned biotech executive bringing decades of experience in strategic development, governance, finance and capital markets to the Company's Board.

Encinitas, California--(Newsfile Corp. - June 25, 2024) - Kiora Pharmaceuticals (NASDAQ: KPRX) has appointed Roger A. Goldberg, MD, MBA, a vitreoretinal surgeon at Bay Area Retina Associates (BARA) to its Scientific Advisory Board.

Kiora Pharmaceuticals (NASDAQ: KPRX ) stock is heading higher on Thursday after the clinical-stage specialty pharmaceutical company announced a $45 million private placement. According to a press release from Kiora Pharmaceuticals, the company has entered into a financing agreement with healthcare-focused institutional investors.

Encinitas, California--(Newsfile Corp. - October 16, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites investors to view the Company's online presentation from the Lytham Partners Fall 2023 Investor Conference taking place on Tuesday October 17, 2023. As part of the presentation, Melisa Tosca, CPA, Kiora's Executive Vice President of Finance, will provide an overview of the Company's business and clinical development pipeline for inherited retinal diseases.

Encinitas, California--(Newsfile Corp. - September 14, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced that results from the ABACUS study of KIO-301 in patients with late-stage retinitis pigmentosa will be presented at the American Academy of Ophthalmology (AAO 2023) conference on November 4, 2023. The late-breaking abstract has been accepted for presentation at the retinal subspecialty day and will include findings from all six participants and 12 evaluated eyes in the Phase 1b, dose-escalating, open-label study.

Kiora Pharmaceuticals (NASDAQ: KPRX ) stock is getting a boost on Wednesday after the company revealed new patents in the U.S. and Europe. According to a press release from Kiora Pharmaceuticals, these patents cover the “local ocular delivery of the KIO-100 family of non-steroidal, anti-inflammatory small molecules.

Kiora Pharmaceuticals (NASDAQ: KPRX ) stock is dropping on Friday after the clinical-stage pharmaceutical company received a delisting notice. That delisting notice comes from the Listing Qualifications Department of the Nasdaq Capital Market.